Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs
- PMID: 21508668
- DOI: 10.4161/cc.10.10.15642
Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs
Abstract
Absence of p53 expression or expression of mutant p53 (mtp53) are common in human cancers and are associated with increased cancer resistance to chemo- and radiotherapy. Therefore, significant efforts towards pharmaceutical reactivation of defective p53 pathways are underway. We previously reported that, in HIPK2 knockdown background, p53 undergoes misfolding with inhibition of DNA binding and transcriptional activities that correlate with increased chemoresistance, and that zinc rescues wild-type p53 activity. Zinc has a crucial role in the biology of p53, in that p53 binds to DNA through a structurally complex domain stabilized by zinc atom. In this study, we explored the role of zinc in p53 reactivation in mutant p53-expressing cancer cells. We found that zinc re-established chemosensitivity in breast cancer SKBR3 (expressing R175H mutation) and glioblastoma U373MG (expressing R273H mutation) cell lines. Biochemical studies showed that zinc partly induced the transition of mutant p53 protein (reactive to conformation-sensitive PAb240 antibody for mutant conformation) into a functional conformation (reactive to conformation-sensitive PAb1620 antibody for wild-type conformation). Zinc-mediated p53 reactivation also reduced the mtp53/p73 interaction restoring both wtp53 and p73 binding to _target gene promoters by ChIP assay with in vivo induction of wtp53 _target gene expression, which rendered mutant p53 cells more prone to drug killing in vitro. Finally, zinc administration in U373MG tumor xenografts increased drug-induced tumor regression in vivo, which correlated with increased wild-type p53 protein conformation. These results show that the use of zinc might restore drug sensitivity and inhibit tumor growth by reactivating mutant p53.
Comment in
-
Zinc, a promising mineral for misfolded p53 reactivation.Cell Cycle. 2011 Aug 1;10(15):2415-6. doi: 10.4161/cc.10.15.15930. Epub 2011 Aug 1. Cell Cycle. 2011. PMID: 21734452 No abstract available.
Similar articles
-
Reversible dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2 knockdown.Cancer Res. 2008 May 15;68(10):3707-14. doi: 10.1158/0008-5472.CAN-07-6776. Cancer Res. 2008. PMID: 18483253
-
A fluorescent curcumin-based Zn(II)-complex reactivates mutant (R175H and R273H) p53 in cancer cells.J Exp Clin Cancer Res. 2013 Oct 7;32(1):72. doi: 10.1186/1756-9966-32-72. J Exp Clin Cancer Res. 2013. PMID: 24220325 Free PMC article.
-
PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein.Int J Oncol. 2009 Nov;35(5):1015-23. doi: 10.3892/ijo_00000416. Int J Oncol. 2009. PMID: 19787255
-
p73 tumor suppressor protein: a close relative of p53 not only in structure but also in anti-cancer approach?Cell Cycle. 2010 Feb 15;9(4):720-8. doi: 10.4161/cc.9.4.10668. Epub 2010 Feb 16. Cell Cycle. 2010. PMID: 20160513 Review.
-
p73-mediated chemosensitivity: a preferential _target of oncogenic mutant p53.Cell Cycle. 2003 Jul-Aug;2(4):348-9. Cell Cycle. 2003. PMID: 12851488 Review. No abstract available.
Cited by
-
Reactivating mutant p53 using small molecules as zinc metallochaperones: awakening a sleeping giant in cancer.Drug Discov Today. 2015 Nov;20(11):1391-7. doi: 10.1016/j.drudis.2015.07.006. Epub 2015 Jul 20. Drug Discov Today. 2015. PMID: 26205328 Free PMC article. Review.
-
The Role of p53 Dysfunction in Colorectal Cancer and Its Implication for Therapy.Cancers (Basel). 2021 May 11;13(10):2296. doi: 10.3390/cancers13102296. Cancers (Basel). 2021. PMID: 34064974 Free PMC article. Review.
-
Elemental Zn and its Binding Protein Zinc-α2-Glycoprotein are Elevated in HPV-Positive Oropharyngeal Squamous Cell Carcinoma.Sci Rep. 2019 Nov 18;9(1):16965. doi: 10.1038/s41598-019-53268-1. Sci Rep. 2019. PMID: 31740720 Free PMC article.
-
Mutant p53 in head and neck squamous cell carcinoma: Molecular mechanism of gain‑of‑function and _targeting therapy (Review).Oncol Rep. 2023 Sep;50(3):162. doi: 10.3892/or.2023.8599. Epub 2023 Jul 14. Oncol Rep. 2023. PMID: 37449494 Free PMC article. Review.
-
Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.Onco_target. 2014 Jul 15;5(13):4603-50. doi: 10.18632/onco_target.2209. Onco_target. 2014. PMID: 25051360 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous